Clinical Significance

Direct Oral Anti-Coagulants (DOACs) are gaining increasing importance in treatment of coagulation disorders. Reversing agents for individual DOACs are already available for therapeutic use but are not yet widely available for lab tests.


This presents the haemostasis laboratory with problems, since a large number of clotting tests are affected to varying degrees by the DOACs contained in patient plasma. For example, a valid thrombophilia diagnosis under the influence of DOACs is not possible to make with conventional clotting tests.


DOAC-Stop is a reagent that makes it possible to eliminate these diagnostic problems. The effect of the DOACs in plasma is neutralized by the addition of a tablet so that the impact on the coagulation tests is minimized.


  1. Exner T., Michalopoulos N. Xavier R., Ahuja M. Simple method for removing DOACs from plasma samples Thrombosis Research, Volume 163, Pages 117–122, 2018       
  2. Kopatz W., Brinkman B.,  Meijers CM. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay Thrombosis Research 170, 97-101, 2018
  3. Favresse J., Lardinoi B., Sabor L. et al. Evaluation of the DOAC-Stop- Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. TH Open 2018;2:e202–e209

Test kit

Adsorption reagent

DOAC-Stop tablets